RTTNews | Nov 23, 2021 08:53AM EST

08:53 Tuesday, November 23, 2021 (RTTNews.com) - Gilead Sciences, Inc. (GILD) said the European Commission has granted marketing authorization for Trodelvy, a first-in-class Trop-2-directed antibody-drug conjugate, as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer.

The company noted that the decision is supported by results from the phase 3 ASCENT study, where Trodelvy reduced the risk of death by 49% and improved median overall survival to 11.8 months versus 6.9 months with chemotherapy. The ASCENT study is a global, open-label, randomized phase 3 study that enrolled more than 500 patients across 230 study locations.

Read the original article on RTTNews ( https://www.rttnews.com/3244416/gilead-sciences-european-commission-grants-marketing-authorization-for-trodelvy.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved